
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NDV-HXP-S-KP.2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NDV-HXP-S-KP.2 Vaccine is a Vaccine candidate, which is currently being evaluated in Phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 10, 2025
Lead Product(s) : NDV-HXP-S-KP.2 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CVAX-01
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : BARDA
Deal Size : $34.0 million
Deal Type : Funding
CastleVax Receives $34M from BARDA to Advance Intranasal NDV-based COVID-19 Vaccine
Details : The funding aims to support the clinical development of CVAX-01 to advance in the mid-stage clinical trial studies for treatment of patients related to Covid-19 infections.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 30, 2024
Lead Product(s) : CVAX-01
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : BARDA
Deal Size : $34.0 million
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NDV-HXP-S
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : US Department Of Health And Human Services
Deal Size : $8.5 million
Deal Type : Funding
Details : The net proceeds from the funding will be used by CastleVax for the advancement of Phase 2 study of a next generation, vector-based intranasal vaccine candidate.
Product Name : NDV-HXP-S
Product Type : Vaccine
Upfront Cash : Undisclosed
October 13, 2023
Lead Product(s) : NDV-HXP-S
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : US Department Of Health And Human Services
Deal Size : $8.5 million
Deal Type : Funding
